A Phase 1b Study of DISC-0974, an Anti-Hemojuvelin Antibody, in Patients with Myelofibrosis and Anemia

Background

Hepcidin, a central regulator of iron homeostasis, is pathologically elevated in patients with myelofibrosis (MF) and anemia. Chronic hepcidin elevation limits iron availability for red blood cell production and contributes to onset and severity of anemia, for which there is a large unmet need for safe and effective treatments. DISC-0974 is an investigational, first-in-class, monoclonal antibody that blocks hemojuvelin, a co-receptor in the bone morphogenetic protein-signaling pathway driving hepcidin expression. A completed healthy volunteer study demonstrated serum hepcidin reductions, serum iron increases, and increasing trends in hematologic parameters, with no safety signal identified.

Aims

This Phase 1b/2, open-label, multiple-ascending dose study (NCT05320198) assessed safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and initial efficacy of DISC0974 in patients with MF and anemia.

Methods

Eligible participants were ≥18 years of age with intermediate-2 or high-risk MF and anemia. Anemia was defined as baseline hemoglobin (Hgb) <10 g/dL with or without intermittent transfusion requirement (non-transfusion dependent [nTD]) or transfusion dependent (TD), as defined by the IWG-MRT. A stable dose of concomitant hydroxyurea and/or Janus kinase (JAK) inhibitor was allowed. Major exclusion criteria included liver iron concentration ≥7 mg/g dry weight and nutritional, genetic, infectious, or autoimmune anemia. Dose escalation was based on a Bayesian optimal interval design with accelerated titration. DISC-0974 was administered subcutaneously monthly for 6 doses. Primary endpoints included evaluating DISC-0974 safety and tolerability. Secondary endpoints included PK/PD markers of iron regulation and hematologic parameters. Hematologic response was defined for TD as transfusion independence (TI) during any 12-week consecutive period and for nTD as ≥1.5 g/dL Hgb increase from baseline at any time point. Durability was evaluated as mean Hgb ≥1.5 g/dL above baseline during any 12-week period. Data were summarized using descriptive statistics.

Results

At the time of data cut, 34 participants were enrolled at 5 dose levels: 14 mg (n=1), 28 mg (n=7), 50 mg (n=12), 75 mg (n=8), and 100 mg (n=6). Treatment with DISC-0974 resulted in meaningful and sustained hepcidin reductions with mean change from baseline (mean 88.2 ng/mL; range [8.7, 374.7]) reaching over 80% across treated participants. This corresponded to iron mobilization at all dose levels.

Efficacy

Hematologic responses were evaluated in participants dosed at 28 to 100 mg. Responses were achieved independent of baseline transferrin saturation (TSAT) values. Initial hematologic responses in nTD participants were observed around the time of administration of the second dose, with a rise in absolute reticulocyte count preceding responses. Mean erythropoietin values decreased from baseline (mean 68.2 mIU/mL; range [13.2, 1815]) in participants treated at 50 to 100 mg. Hemoglobin responses were achieved in 69% (20/29) of nTD participants; 60% of nTD participants (9/15) achieved a durable response. TSAT values above normal range (50%) were observed in all participants with a durable response. One of two evaluable TD participants achieved TI at the end of study. All evaluable participants with a baseline transfusion requirement (n=8) had ≥50% reduction in transfusions over a rolling 8-week window compared to baseline. Hematologic response was observed in 6 of 10 participants with concomitant JAK inhibitor therapy.

Safety

One adverse event (AE), diarrhea, was at least possibly related to DISC-0974 and reported in ≥2 participants. Grade 3 AEs included headache reported in 1 participant treated at 28 mg (not related to DISC-0974) and Grade 3 anemia reported in 2 participants treated at 28 mg and 4 participants treated at 50 mg (1 at 50 mg was deemed related to DISC-0974; all others were deemed not related). One serious AE of Grade 2 arthralgia was reported and deemed not related to DISC-0974.

Summary/Conclusions

DISC-0974 demonstrated acceptable safety and tolerability at all evaluated dose levels. Hematologic responses were achieved in nTD and TD participants, regardless of concomitant JAK inhibitor use. Sustained hepcidin reduction with DISC-0974 led to increased serum iron that preceded hematological response. Additional Phase 1b data, including longer follow-up, will be presented.

Gangat:Agios: Other: Advisory Board; DISC Medicine: Consultancy, Other: Advisory Board . Halpern:Incyte Corporation: Research Funding; Jazz: Research Funding; Gilead: Research Funding; AbbVie: Consultancy; Disc Medicine: Research Funding; Karyopharm Therapeutics: Research Funding; Agios: Consultancy; Bayer: Research Funding; Imago Biosciences: Research Funding; Notable Lab: Consultancy. Rampal:Galecto: Consultancy; Kartos: Consultancy; AbbVie: Consultancy; Constellation/MorphoSys: Consultancy, Research Funding; Sumitomo Dainippon: Consultancy; Sierra Oncology/GSK: Consultancy; Protagonist: Consultancy; Cogent: Consultancy; Servier: Consultancy; Zentalis: Consultancy, Research Funding; Karyopharm: Consultancy; Ryvu: Research Funding; Disc Medicine: Consultancy; PharmaEssentia: Consultancy; Incyte Corporation: Consultancy, Research Funding; Jubilant: Consultancy; CTI BioPharma: Consultancy; Stemline Therapeutics: Consultancy, Research Funding; Blueprint: Consultancy; Celgene/BMS: Consultancy; Jazz Pharmaceuticals: Consultancy; Novartis: Consultancy; Promedior: Consultancy. Bose:Ionis Pharmaceuticals: Research Funding; CTI Biopharma Corp: Honoraria, Research Funding; Telios: Research Funding; Astellas: Research Funding; Incyte: Honoraria, Research Funding; Kartos: Honoraria, Research Funding; Pfizer: Research Funding; Cogent: Honoraria, Research Funding; Novartis: Honoraria; MorphSys: Honoraria, Research Funding; PharmaEssentia: Honoraria; BMS: Honoraria, Research Funding; Karyopharm: Honoraria; Blueprint: Honoraria, Research Funding; GSK: Honoraria; AbbVie: Honoraria; Disc Medicine: Research Funding; NS Pharma: Research Funding; Promedior: Research Funding. Hexner:Disc Medicine: Consultancy. Talpaz:Arcus: Research Funding; BMS: Membership on an entity's Board of Directors or advisory committees, Research Funding; Imago: Membership on an entity's Board of Directors or advisory committees; KyowaKirin: Membership on an entity's Board of Directors or advisory committees; Sumitomo: Membership on an entity's Board of Directors or advisory committees; SierraOncology: Membership on an entity's Board of Directors or advisory committees; GSK: Membership on an entity's Board of Directors or advisory committees; Pfizer: Membership on an entity's Board of Directors or advisory committees. Michaelis:Disc Medicine: Consultancy; Kura Oncology: Consultancy; Merck Pharmaceuticals: Consultancy, Honoraria; Nkarta: Consultancy. Islam:Disc Medicine: Consultancy. Swords:Disc Medicine: Consultancy. Bhatt:Disc Medicine: Current Employment, Current holder of stock options in a privately-held company. Buch:Disc Medicine: Current Employment, Current equity holder in publicly-traded company. Pelletier:Disc Medicine: Consultancy, Current equity holder in publicly-traded company. Savage:Disc Medicine: Current Employment, Current equity holder in publicly-traded company.